NKGen Biotech, Inc. Common Stock (NKGN)
Automate Your Wheel Strategy on NKGN
With Tiblio's Option Bot, you can configure your own wheel strategy including NKGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NKGN
- Rev/Share 0.0
- Book/Share -1.615
- PB -0.1926
- Debt/Equity -0.6533
- CurrentRatio 0.0245
- ROIC 13.8762
- MktCap 23247312.0
- FreeCF/Share -0.7175
- PFCF -1.1122
- PE -0.1869
- Debt/Assets 2.05
- DivYield 0
- ROE 0.9607
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
NKGen Biotech Chairman & CEO Paul Y. Song, M.D.
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed AlpineBrook convertible notes.
Read More
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
SANTA ANA, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that on March 3, 2025 it received notice that the Nasdaq Hearings Panel determined to delist the Company's common stock from the Nasdaq Global Market after the close of trading on March 4, 2025, solely due to the Company's continued failure to comply with Rule 5450(b)(2)(A) of Nasdaq's Listing Requirements, related to the market value of its common stock. After delisting from Nasdaq, the …
Read More
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options. NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options.
Read More
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator (“PI”) for its Phase 2a clinical trial of troculeucel, expanded enhanced autologous NK cell therapy, for the treatment of moderate Alzheimer's disease (NCT06189963). In addition to Dr. Fletcher's appointment as National PI, NKGen is pleased to announce AdventHealth Research Institute, Neuroscience Research in Orlando will be the first …
Read More
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse events following troculeucel therapy. Troculeucel therapy was well-tolerated and resulted in beneficial effects on protein aggregate levels and neuroinflammatory biomarkers in the cerebrospinal fluid, with decreases in pTau181 and GFAP appearing to be dose dependent.
Read More
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Fast Track designation accelerates troculeucel's path to U.S. FDA submission for the treatment of patients with moderate Alzheimer's disease. NKGen will benefit from increased FDA interactions, enhanced visibility and potential eligibility for Accelerated Approval, Priority Review, and Rolling Review of the regulatory dossier, with a faster path to market for troculeucel.
Read More
About NKGen Biotech, Inc. Common Stock (NKGN)
- IPO Date 2023-10-02
- Website https://www.grafacq.com
- Industry Biotechnology
- CEO Dr. Paul Y. Song M.D.
- Employees 63